Parsaclisib
- Generic Name
- Parsaclisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22ClFN6O2
- CAS Number
- 1426698-88-5
- Unique Ingredient Identifier
- OS7097575K
- Background
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
- Associated Conditions
- -
- Associated Therapies
- -
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Registration Number
- NCT05867030
Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05238064
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05083208
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04849715
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT04831996
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Prism Research, Saint Paul, Minnesota, United States
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT04831944
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04809467
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04796922
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
- Conditions
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaT-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Transformed Mycosis FungoidesRecurrent Transformed Mycosis FungoidesRecurrent Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Walter Hanel
- Target Recruit Count
- 5
- Registration Number
- NCT04774068
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 65
- Registration Number
- NCT04661007
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Chiba Cancer Center, Chiba, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.